Laboratoire d'Immunologie, Cellular Immunology Laboratory, Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon E - 5 place d'Arsonval, Lyon Cedex 03 69437, France; EA 7426 PI3 "Pathophysiology of Injury-induced Immunosuppression", Université Claude Bernard Lyon I, Hospices Civils de Lyon, bioMérieux, Hôpital Edouard Herriot, Place d'Arsonval, Lyon Cedex 03 69437, France.
EA 7426 PI3 "Pathophysiology of Injury-induced Immunosuppression", Université Claude Bernard Lyon I, Hospices Civils de Lyon, bioMérieux, Hôpital Edouard Herriot, Place d'Arsonval, Lyon Cedex 03 69437, France; Departement of Anesthesiology, Hospices Civils de Lyon, Hôpital Edouard Herriot, Pavillon E - 5 place d'Arsonval, Lyon Cedex 03 69437, France.
Crit Care Clin. 2018 Jan;34(1):97-106. doi: 10.1016/j.ccc.2017.08.007. Epub 2017 Oct 6.
It is now well established that profound immunosuppression develops within a few days after sepsis onset in patients. This should be considered additional organ failure because it is associated with increased rate of nosocomial infections, mortality, and long-term complications, thus constituting the rationale for immunomodulation in patients. Nevertheless, the demonstration of the efficacy of such therapeutic strategy in improving deleterious outcomes in sepsis remains to be made. Results from clinical trials based on interleukin 7 and granulocyte macrophage colony-stimulating factor immunoadjuvant therapies in septic shock patients are expected for 2018.
现在已经证实，在脓毒症发病后的几天内，患者会出现严重的免疫抑制。这应被视为额外的器官衰竭，因为它与医院获得性感染、死亡率和长期并发症的增加有关，因此构成了对患者进行免疫调节的理由。然而，这种治疗策略在改善脓毒症不良结局方面的疗效仍有待证明。预计 2018 年会有基于白细胞介素 7 和粒细胞-巨噬细胞集落刺激因子免疫佐剂疗法治疗脓毒性休克患者的临床试验结果。
